2 medical tech ASX shares Morgans loves right now

Growth stocks have fallen out of favour with investors, but one investment house is keeping the faith in this pair of health device makers.

| More on:
a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Medical and biotechnology ASX shares have suffered greatly the past few months as the prospect of rising interest rates scares people off future-dependent sectors.

But the team at Morgans believes there are still a couple of medical tech stocks that are big enough and profitable enough to be worth buying at the current discount.

Let’s take a look at the pair, as recommended by analyst Andrew Tang:

‘Maintains a dominant position’

The Cochlear Limited (ASX: COH) share price has largely gone sideways over the past 12 months, gaining just 2.3%. Year-to-date is similar, showing a 1.8% rise.

The hearing device company took a hit from the COVID-19 pandemic, which saw fewer patients seeking treatments for non-respiratory issues.

There were also investors who were not fans of Cochlear’s recent acquisition of Oticon Medical.

But, for Tang, there is no reason why Cochlear won’t recover to its pre-COVID glory.

“Cochlear maintains a dominant position in the implantable hearing solutions segment,” he wrote in Morgans Best Ideas for May.

“While we continue to believe a full recovery from COVID-based disruptions still has time to play out, improving demand and strong pipeline — coupled with management’s increasing confidence — suggests an improving earnings profile.”

According to CMC Markets, eight out of 20 analysts recommend Cochlear shares as a buy, while nine rate it as a hold.

Short-term pain for long-term gains

Sleep breathing device maker Resmed CDI (ASX: RMD) has recently seen its stocks wade through far choppier waters than Cochlear.

The volatility is seen in how the share price has lost more than 21% for the year but gained 13% over the past 12 months.

Tang believes the rollercoaster ride will continue for a while yet.

“We believe the next few quarters will likely be volatile, as COVID-related demand for ventilators continues to slow and core sleep apnoea volumes gradually lift.”

But the Morgans team still has plenty of conviction in Resmed over the long term.

“Nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.”

Goldman Sachs analysts agree with Morgans, rating Resmed as a buy with a price target of $33.70.

“The broker believes ResMed is still in a stronger position today than 12 months ago and does not believe the near term challenges should be overcapitalised,” reported The Motley Fool’s James Mickleboro last week.

Indeed, 13 out of 23 analysts surveyed in CMC Markets rate the stock as a “strong buy”, with another three labelling it a “moderate buy”.

Motley Fool contributor Tony Yoo has positions in Cochlear Ltd. and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

What’s the outlook for the CSL share price in July?

We take a look at what the experts are saying about the biotech company's shares.

Read more »

Photo of a group of scientists cheering while working in a lab as the Race Oncology share price skyrockets today on positive study results
Healthcare Shares

Why is the Race Oncology share price soaring 13% today?

New trial results have excited ASX investors.

Read more »

Rising arrow on a blue graph symbolising a rising share price.
Healthcare Shares

Starphama share price lunges 5% on product relaunch

Early support for Starphama on Thursday has it off to a great start.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Why is the Paradigm share price rocketing 20% higher today?

The Paradigm share price is having a very strong day...

Read more »

A businessman presents a company annual report in front of a group seated at a table
Healthcare Shares

Own Immutep shares? Here are 3 takeaways from the company’s investor update

Investors were mute to the update.

Read more »

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.
Healthcare Shares

Has CSL been growing its dividend?

Is the biotech giant still increasing its dividends in a post-COVID world?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Why is the 4DMedical share price exploding 40% today?

4DMedical signed a three-year, nationwide contract with I-MED Radiology Network.

Read more »

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Healthcare Shares

What was the Sonic Healthcare share price when it first listed on the ASX?

Sonic Healthcare has an interesting history...

Read more »